


**AMENDMENTS TO THE CLAIMS**

**CLAIMS**

1. **(Currently Amended)** A method for the treatment or prophylaxis of parasitic infections, such as malaria, in man or a zoonose vector comprising the administration of an effective amount of a compound of formula I to a patient in need thereof, or to the vector Use of a compound according to formula I, in the manufacture of a medicament for the treatment or prophylaxis of parasitic infections in mammals, including man:



where

R<sup>1</sup> is H, C<sub>1</sub>-C<sub>5</sub> alkyl, C<sub>2</sub>-C<sub>5</sub> alkenyl, C<sub>2</sub>-C<sub>5</sub> alkynyl or a 5 or 6 membered, saturated or unsaturated ring containing 0 to 3 heteroatoms selected from N, O and S, the alkyl, alkenyl, alkynyl or ring being independently optionally substituted with R<sup>4</sup>;

D is -NHCO-, -CONH-, -O-, -C(=O)-, -CH=CH, -C≡C-, -NR<sup>5</sup>-;

R<sup>4</sup> is hydrogen, halo, cyano, amino, nitro, carboxy, carbamoyl, hydroxy, oxo, C<sub>1</sub>-C<sub>5</sub> alkyl, C<sub>1</sub>-C<sub>5</sub> haloalkyl, C<sub>1</sub>-C<sub>5</sub> alkyloxy, C<sub>1</sub>-C<sub>5</sub> alkanoyl, C<sub>1</sub>-C<sub>5</sub> alkanoyloxy, C<sub>1</sub>-C<sub>5</sub> alkylthio, -N(C<sub>0</sub>-C<sub>3</sub>-alkyl)<sub>2</sub>, hydroxymethyl, aminomethyl, carboxymethyl; -SO<sub>2</sub>N(C<sub>0</sub>-C<sub>3</sub>-alkyl), -SO<sub>2</sub>C<sub>1</sub>-C<sub>5</sub>-alkyl;

R<sup>5</sup> is H, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkanoyl;

E is Si or C;

R<sup>6</sup>, R<sup>7</sup> and R<sup>8</sup> are independently selected from C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, C<sub>2</sub>-C<sub>8</sub> alkynyl or a stable monocyclic, bicyclic or tricyclic ring system which is saturated or unsaturated in which each ring has 0 to 3 heteroatoms selected from N, O and S,

R<sup>6</sup>, R<sup>7</sup> and R<sup>8</sup> are independently optionally substituted with R<sup>4</sup>;

G is -O-, -S-, -CHR<sup>10</sup>-, -C(=O)-;

J is -CH<sub>2</sub>-, or when G is CHR<sup>10</sup> may also be -O- or -NH-;

R<sup>10</sup> is H, F, -CH<sub>3</sub>, -CH<sub>2</sub>NH<sub>2</sub>, -CH<sub>2</sub>OH, -OH; or a pharmaceutically acceptable ether, amide or ester thereof

R<sup>11</sup> is H, F, -CH<sub>3</sub>, -CH<sub>2</sub>NH<sub>2</sub>, -CH<sub>2</sub>OH, CH(OH)CH<sub>3</sub>, CH(NH<sub>2</sub>)CH<sub>3</sub>; or a pharmaceutically acceptable ether, amide or ester thereof; or

R<sup>10</sup> and R<sup>11</sup> together define an olefinic bond, or together form a -CH<sub>2</sub>-group, thereby defining a *cis* or *trans* cyclopropyl group;

and pharmaceutically acceptable salts thereof.

2. **(Currently Amended)** The method according to claim 1, wherein G is -O- or -CH<sub>2</sub>-.
3. **(Currently Amended)** The method according to claim 1 wherein R<sup>10</sup> and R<sup>11</sup> define an olefinic bond or a cyclopropyl group.
4. **(Currently Amended)** The method Use of a compound according to claim 1, wherein R<sup>11</sup> is H; CH<sub>2</sub>OH or a pharmaceutically acceptable ether or ester thereof; or CH<sub>2</sub>NH<sub>2</sub> or a pharmaceutically acceptable amide thereof.
5. **(Currently Amended)** The method Use of a compound according to claim 1, wherein R<sup>1</sup> is H.
6. **(Currently Amended)** The method Use of a compound according to claim 1, wherein D is -O- or -NH-.
7. **(Currently Amended)** The method Use of a compound according to claim 6, wherein C<sub>0</sub>.C<sub>3</sub>-alkylene-D-C<sub>0</sub>.C<sub>3</sub>-alkylene is oxymethylene, oxyethylene or oxypropylene.
8. **(Currently Amended)** The method Use of a compound according to claim 6, wherein C<sub>0</sub>.C<sub>3</sub>-alkylene-D-C<sub>0</sub>.C<sub>3</sub>-alkylene is aminomethylene, aminoethylene or aminopropylene.

9. **(Currently Amended)** Use of a compound The method according to claim 1, wherein at least two of R<sup>6</sup>, R<sup>7</sup> and R<sup>8</sup> are aryl.


10. **(Currently Amended)** The method Use of a compound according to claim 1, wherein R<sup>6</sup> is optionally substituted phenyl.

11. **(Currently Amended)** The method Use of a compound according to claim 10 wherein R<sup>8</sup> is optionally substituted phenyl or pyridyl.

12. **(Currently Amended)** The method Use of a compound according to claim 1 wherein E is C.

13. **(Currently Amended)** The method Use according to any preceding claim, wherein the zoonose vector is a parasite is and a Plasmodium species.

14. **(Currently Amended)** A compound of the formula II:



II

where

R<sup>1</sup> is H, C<sub>1</sub>-C<sub>5</sub> alkyl, C<sub>2</sub>-C<sub>5</sub> alkenyl, C<sub>2</sub>-C<sub>5</sub> alkynyl or a 5 or 6 membered, saturated or unsaturated ring containing 0 to 3 heteroatoms selected from N, O and S, the alkyl, alkenyl, alkynyl or ring being independently optionally substituted with R<sup>4</sup>;

D is -NHCO-, -CONH-, -O-, -C(=O)-, -CH=CH, -C≡C-, -NR<sup>5</sup>-;

R<sup>4</sup> is hydrogen, halo, cyano, amino, nitro, carboxy, carbamoyl, hydroxy, oxo, C<sub>1</sub>-C<sub>5</sub> alkyl, C<sub>1</sub>-C<sub>5</sub> haloalkyl, C<sub>1</sub>-C<sub>5</sub> alkyloxy, C<sub>1</sub>-C<sub>5</sub> alkanoyl, C<sub>1</sub>-C<sub>5</sub> alkanoyloxy, C<sub>1</sub>-C<sub>5</sub> alkylthio, -N(C<sub>0</sub>-C<sub>3</sub>-alkyl), hydroxymethyl, aminomethyl, carboxymethyl; -SO<sub>2</sub>N(C<sub>0</sub>-C<sub>3</sub>-alkyl), -SO<sub>2</sub>C<sub>1</sub>-C<sub>5</sub>-alkyl;

R<sup>5</sup> is H, C<sub>1</sub>-C<sub>4</sub>-alkyl, C<sub>1</sub>-C<sub>4</sub>-alkanoyl;

E is Si or C;

R<sup>6</sup> and R<sup>7</sup> are independently selected from a stable monocyclic, bicyclic or tricyclic ring system

which has an aromatic nature wherein each ring has 0 to 3 heteroatoms selected from N, O and S

R<sup>8</sup> is selected from C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, C<sub>2</sub>-C<sub>8</sub> alkynyl, or a stable monocyclic, bicyclic or tricyclic ring system which is saturated or unsaturated in which each ring has 0 to 3 heteroatoms selected from N, O and S;

R<sup>6</sup>, R<sup>7</sup> and R<sup>8</sup> are independently optionally substituted with R<sup>4</sup>;

G is -O-, -S-, -CHR<sup>10</sup>-, -C(=O)-;

J is -CH<sub>2</sub>-; or when G is CHR<sup>10</sup> may also be -O- or -NH-;

R<sup>10</sup> is H, F, -CH<sub>3</sub>, -CH<sub>2</sub>NH<sub>2</sub>, -CH<sub>2</sub>OH, -OH; or a pharmaceutically acceptable ether, amide or ester thereof;

R<sup>11</sup> is H, F, -CH<sub>3</sub>, -CH<sub>2</sub>NH<sub>2</sub>, -CH<sub>2</sub>OH, -CH(OH)CH<sub>3</sub>, CH(NH<sub>2</sub>)CH<sub>3</sub> or a pharmaceutically acceptable ether, amide or ester thereof; or

R<sup>10</sup> and R<sup>11</sup> together define an olefinic bond, or together form a -CH<sub>2</sub>-group, thereby defining a *cis* or *trans* cyclopropyl group;

and pharmaceutically acceptable salts thereof.

15. (Original) A compound according to claim 14 wherein G is -O- or -CH<sub>2</sub>-.

16. (Original) A compound according to claim 14 wherein R<sup>10</sup> and R<sup>11</sup> define an olefinic bond or a cyclopropyl group.

17. (Original) A compound according to claim 14, wherein R<sup>11</sup> is H; CH<sub>2</sub>OH or a pharmaceutically acceptable ether or amide thereof, or CH<sub>2</sub>NH<sub>2</sub> or a pharmaceutically acceptable amide thereof.

Rule 18. **(Original)** A compound according to claim 14, wherein R<sup>1</sup> is H.  
1.126

19. ~~20.~~ **(Original)** A compound according to claim 14, wherein D is -O- or -NH-.

20. ~~21.~~ **(Original)** A compound according to claim 20, wherein C<sub>0</sub>C<sub>3</sub>-alkylene-D-C<sub>0</sub>C<sub>3</sub>-alkylene is oxymethylene, oxyethylene or oxypropylene.

21. ~~22.~~ **(Original)** A compound according to claim 20, wherein C<sub>0</sub>C<sub>3</sub>-alkylene-D-C<sub>0</sub>C<sub>3</sub>-alkylene is aminomethylene, aminoethylene or aminopropylene.


22. ~~23.~~ **(Original)** A compound according to claim 14, wherein R<sup>6</sup> is optionally substituted phenyl.

23. ~~24.~~ **(Original)** A compound according to claim 23 wherein R<sup>8</sup> is optionally substituted phenyl or pyridyl.

24. ~~25.~~ **(Original)** A compound according to claim 14 wherein E is C.

25. ~~26.~~ **(Currently Amended)** A pharmaceutical composition comprising a compound as defined in any preceding claim 1 and a pharmaceutically acceptable carrier or diluent therefore.

26. ~~27.~~ **(NEW)** A compound of the formula II:



where

R<sup>1</sup> is H, C<sub>1</sub>-C<sub>5</sub> alkyl, C<sub>2</sub>-C<sub>5</sub> alkenyl, C<sub>2</sub>-C<sub>5</sub> alkynyl or a 5 or 6 membered, saturated or unsaturated ring containing 0 to 3 heteroatoms selected from N, O and S, the alkyl, alkenyl, alkynyl or ring being independently optionally substituted with R<sup>4</sup>;

D is -NHCO-, -CONH-, -O-, -C(=O)-, -CH=CH-, -C≡C-, -NR<sup>5</sup>-;

R<sup>4</sup> is hydrogen, halo, cyano, amino, nitro, carboxy, carbamoyl, hydroxy, oxo, C<sub>1</sub>-C<sub>5</sub> alkyl, C<sub>1</sub>-C<sub>5</sub> haloalkyl, C<sub>1</sub>-C<sub>5</sub> alkyloxy, C<sub>1</sub>-C<sub>5</sub> alkanoyl, C<sub>1</sub>-C<sub>5</sub> alkanoyloxy, C<sub>1</sub>-C<sub>5</sub> alkylthio, -N(C<sub>0</sub>-C<sub>3</sub>-alkyl)<sub>2</sub>, hydroxymethyl, aminomethyl, carboxymethyl; -SO<sub>2</sub>N(C<sub>0</sub>-C<sub>3</sub>-alkyl), -SO<sub>2</sub>C<sub>1</sub>-C<sub>5</sub>-alkyl;

R<sup>5</sup> is H, C<sub>1</sub>-C<sub>4</sub>-alkyl, C<sub>1</sub>-C<sub>4</sub>-alkanoyl;

E is Si or C;

R<sup>6</sup> and R<sup>7</sup> are independently selected from a stable monocyclic, bicyclic or tricyclic ring system which has an aromatic nature wherein each ring has 0 to 3 heteroatoms selected from N, O and S

R<sup>8</sup> is selected from C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, C<sub>2</sub>-C<sub>8</sub> alkynyl, or a stable monocyclic, bicyclic or tricyclic ring system which is saturated or unsaturated in which each ring has 0 to 3 heteroatoms selected from N, O and S;

R<sup>6</sup>, R<sup>7</sup> and R<sup>8</sup> are independently optionally substituted with R<sup>4</sup>;

G is -S-, -CHR<sup>10</sup>-, -C(=O)-;

J is -CH<sub>2</sub>-, or when G is CHR<sup>10</sup> J may also be -O- or -NH-;

R<sup>10</sup> is H, F, -CH<sub>3</sub>, -CH<sub>2</sub>NH<sub>2</sub>, -CH<sub>2</sub>OH; or a pharmaceutically acceptable ether, amide or ester thereof

R<sup>11</sup> is CH<sub>2</sub>OH; or a pharmaceutically acceptable ether, amide or ester thereof; or

R<sup>10</sup> and R<sup>11</sup> together define an olefinic bond, or together form a -CH<sub>2</sub>-group, thereby defining a cis or trans cyclopropyl group;

and pharmaceutically acceptable salts thereof.